ABSTRACT -The present study was undertaken to estimate the usefulness of genomic approaches to predict hepatotoxicity. Male rats were treated with acetaminophen (APAP), carbon tetrachloride (CCL), amiodarone (AD) or tetracycline (TC) at toxic doses. Their livers were extracted 6 or 24 hr after the dosings and were used for subsequent examinations. At 6 hr there were no histological changes noted in any of the groups except for the CCL group, but at 24 hr, such changes were noted in all but the AD group. Regarding genomic analysis, we performed hierarchical cluster analysis using S-plus software. The individual microarray data were clearly classified into 5 treatment-related clusters at 24 hr as well as at 6 hr, even though no morphological changes were noted at 6 hr. In the gene expression analysis using GeneSpring, transcription factor and oxidative stress-and lipid metabolism-related genes were markedly affected in all treatment groups at both time points when compared with the corresponding control values. Finally, we investigated gene networks in the above-affected genes by using Ingenuity Pathway Analysis software. Down-regulation of lipid metabolism-related genes regulated by SREBP1 was observed in all treatment groups at both time points, and up-regulation of oxidative stress-related genes regulated by Nrf2 was observed in the APAP and CCL treatment groups. From the above findings, for the application of genomic approaches to predict hepatotoxicity, we considered that cluster analysis for classification and early prediction of hepatotoxicity and network analysis for investigation of toxicological biomarkers would be useful.
INTRODUCTION
Safety evaluation in drug development has become recently charged with predicting the potential adverse effects of drugs in humans. Therefore, investigation of toxicological mechanisms or toxic biomarkers is noticed more and more. The omic technologies are more helpful than traditional safety evaluation for investigation of these matters. In several studies using omic technologies, the toxicological mechanism or potential biomarkers were revealed (Fukushima et al., 2005; Yamamoto et al., 2005; Vickers et al., 2004; Mortishire-Smith et al., 2004; Sawada et al., 2005) . Investigations using genomic approaches such as DNA microarray have especially increased in number. The DNA microarray can provide a huge amount of data, which is an advantage. However, at the same time, there is a disadvantage, i.e., the complexity of these data. Therefore it is necessary to use analytical tools such as hierarchical cluster analysis or principal component analysis (PCA) to analyze the vast data. These tools have already been used in several toxicology studies (Huang et al., 2004; Yamamoto et al., 2006) . Furthermore, Ingenuity Pathway Analysis software was recently developed to investigate drug effects in studies generating huge amounts of microarray data. This system comprises a huge database of genes and shows the regulation of or relationships among the genes. Also, the system can make a gene network map based on this database, and thus allows us to understand the mechanism or function of the drug effects. However, this pathway analysis has not been previously used in the field of toxicology.
The liver is one of the most important organs, owing to its biological functions such as drug metabolism, amino acid metabolism, lipid metabolism and glycolysis. Although many studies using genomic approaches on the liver have been performed, the use of this organ is still insufficient for evaluating toxicity in the early phase of drug development. For the purpose of applying genomic approaches to early prediction of hepatotoxicity, we used 4 hepatotoxicants, i.e., acetaminophen (APAP), carbon tetrachloride (CCL), amiodarone (AD), and tetracycline (TC) at toxic doses in the current study. APAP is known to induce hepatocellular necrosis by causing depletion of GSH (Mitchel et al., 1973; Pumford et al., 1997) . CCL induces hepatocellular necrosis and steatosis via the production of the free radical CCl 3 (Weber et al., 2003) . AD has been shown to induce steatosis in the liver by inhibiting the mitochondrial beta-oxidation of fatty acids (Fromenty et al., 1990) , as well as causing phospholipidosis (Lewis et al., 1990; Reasor and Kacew, 2001 ) in the organ. TC also inhibits hepatic mitochondrial fatty acid beta-oxidation and then produces microvesicular steatosis in the liver (Freneaux et al., 1988; Lettéron et al., 2003) .
The present study was undertaken to apply hierachical cluster analysis and pathway analysis to the prediction of hepatotoxicity in male rats treated with a single dose of each of the above 4 compounds. Their effects on liver histology and gene expression were examined at 6 and 24 hr after dosing by using several analytical tools such as the GeneChip microarray, GeneSpring for gene expression analysis, S-plus for hierarchical cluster analysis, and Ingenuity Pathway Analysis software for investigation of the toxicological mechanism as a biomarker. Real-time RT-PCR analysis was also performed for confirming gene expression.
MATERIALS AND METHODS

Animals and treatment
Six-week-old male Crj:CD(SD)IGS rats (n=45) were purchased from Charles River Japan, Inc. (Kanagawa Japan). The animals were acclimated to our laboratory for 7 days prior to treatment and then randomly assigned to a control group and 4 treatment groups of acetaminophen (APAP), carbon tetrachloride (CCL), amiodarone (AD), and tetracycline (TC) according to their body weight. The animals were housed in individual cages and maintained under controlled conditions of light (12-hr light/12-hr dark cycle) and temperature (23 to 25°C) and allowed to eat pelleted feed and drink municipal drinking water ad libitum. The rats were administered APAP (Sigma, St. Louis. MO), AD (ICN Biomedicals Inc. Aurora, OH, U.S.A), TC (Wako, Osaka) or CCL (Wako) once by oral gavage at a dose of 1000 mg/kg for APAP and AD, 2000 mg/kg for TC, and 1 mL/kg for CCL. Five animals were administered the vehicle, 0.5% (w/v) methylcellulose (Metolose ® SM-4000, Shin-Etsu Chemical Co., Ltd., Tokyo) aqueous solution containing 0.1% Polysorbate 80 (Tween ® 80, ICN Biomedicals, Inc), in the same manner and served as the controls. The dose levels were set as toxicological levels determined by several previous studies. Six or 24 hr after dosing, all rats were euthanized under isoflurane inhalation anesthesia and their livers removed. The right lobe of the liver was prefixed in 4% neutral buffered paraformaldehyde for pathological examination, whereas the left lobe was frozen and stored in liquid nitrogen until used for the gene expression analyses. All procedures involving animals were approved by the Animal Ethics Committee of Pfizer Global Research & Development Nagoya Laboratories, and were performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals (National Academy of Sciences, 1996) .
Pathological examination
The fixed liver was trimmed, dehydrated, embedded in paraffin, sectioned, mounted on glass slides, stained with hematoxylin and eosin and examined by light microscopy.
RNA extraction
Total RNA was extracted from the frozen liver of each animal by using TRIZOL Reagent (Invitrogen Corp. Carlsbad, CA, U.S.A) and was purified with an RNeasy column (Qiagen, Tokyo). The quality of purified total RNA was checked by using an Agilent 2100 Bioanalyzer (Agilent Technologies, Tokyo), and then the total RNA was used for microarray analysis and real-time RT-PCR.
Microarray analysis
After double-stranded cDNA had been synthesized from 500 ng of template total RNA by using a One-Cycle cDNA Synthesis kit (Affimetrix, Tokyo), the cDNA synthesized from each animal was applied to synthesize biotin labeled cRNA using an IVT Labeling kit (Affimetrix). The labeled cRNA was purified with an RNeasy column (Qiagen), and the quality of Vol. 31 No. 5 the cRNA were checked by conducting gel electrophoresis. Fifteen micrograms of the purified cRNA we r e f r ag m e n te d wi th f ra g m e n ta ti o n bu ff e r (GeneChip ® Sample cleanup module, Affimetrix), and the fragmented cRNA hybridized to GeneChip ® Rat 230-2 (Affimetrix) overnight at 45°C. These arrays were washed and stained automatically by using a Fluidics Station 450 (Affimetrix), and then the microarrays were scanned by using a GeneChip ® Scanner 3000 with Workstation (Affimetrix). The microarray data were globally normalized by using the GeneChip ® Operating Software Server 1.0 (GCOS Server, Affimetrix), and the normalized data were used for further analysis.
Hierarchical analysis
At first, because each of the above microarray data contained positive or negative control signals, these data were deleted from the array data, and thus the gene expression data from a total of 31042 elements on the microarray were applied to this analysis. Secondly, any value lower than 25 was taken as 25; and finally these data files were transported to S-plus 6.1 (Mathematical Systems Inc. Tokyo) and then hierarchical analysis performed on the 6-and 24-hr groups.
Gene expression analysis using GeneSpring
The gene expression data from a total of 31042 elements on the microarray for each animal was applied to this gene expression analysis as well as to hierarchical analysis. The change in each gene expression was calculated by determining the fold change (ratio) of the mean intensity of each group by using GeneSpring version 7.2 (Agilent Technologies). A 1.2-1.3 fold increase or decrease in the intensities for the APAP-, CCL-, AD-, and TC-treated groups at 6 or 24 hr after dosing compared with the control for each time point was regarded as a significant change in the gene expression. For the genes selected by this threshold, there were no internal controls, e.g., beta-actin or glyceraldehyde-3-phosphate dehydrogenase, for any of the microarray data from any of the animals. The above selected genes were categorized into 6 functional categories referred to as "Gene Ontology."
Pathway analysis
The accession numbers and fold changes of the above-selected genes, lipid metabolism-, transcription factor-and oxidative stress-related genes in each treatment group were imported into the Ingenuity Pathway Analysis software (Ingenuity Systems, CA, U.S.A).
Real-time RT-PCR analysis
We performed real-time RT-PCR by using an Applied Biosystems 7900HT Fast Real-Time PCR System. One microgram of the purified total RNA extracted from the liver of each animal was reversetranscribed individually with SuperScript II reverse transcriptase (Invitrogen Corp.) and oligo-dT 12-18(Invitrogen Corp.). The expression of each of the following was measured: sterol regulatory element binding protein 1 (SREBP1), nuclear factor (erythroidderived 2)-like 2 (Nrf2), glutathione reductase (GSR), heme oxygenase 1 (HMOX1), thioredoxine reductase 1 (TXNRD1), sterol-CoA desaturase (SCD) and fatty acid synthase (FASN). The primer sequences were designed by using Primer Express software (Applied Biosystems), and the primer sequences are indicated in Table 1 . A standard curve was also run for each PCR reaction. The Platinum SYBR Green qPCR SuperMix-UDG (Invitorogen Corp) was used for the real-time RT-PCR analysis. Individual values were normalized based on the value of beta actin. The relative gene expression was calculated by setting the control at 1.
Statistical analysis
Data were statistically analyzed by using Student's t-test (Gad and Weil, 1982) . A probability of less than 5% was considered statistically significant. Table 2 summarizes the histopathological changes in the liver of all groups. In the 6-hr treatment groups of APAP, TC, and AD, there were no histopathological changes. However, in the 24-hr treatment groups for the above compounds, the following changes were noted: eosinophilic changes, necrosis and inflammatory cell infiltration for APAP, slight inflammatory cells infiltration for AD, and fatty changes and focal inflammatory cells infiltration for TC. On the other hand, in the CCL treatment group, centrilobular fatty changes with the appearance of foamy structure, swelling of hepatocytes, and centrilobular necrosis were observed at both time points. The grade of change at 24 hr was higher than that at 6 hr. Fig. 1 shows the result of the cluster analysis. There were 5 clusters at both time points. Furthermore, the animals treated with the same compounds were gathered in the same cluster. The 5 clusters correlated well with the treatment compounds. At both time points, one or three outliers were observed. These samples were not used for further analyses because they were not considered to be reflective of the toxicological signature.
RESULTS
Histopathological changes in the liver
Hierarchical cluster analysis
Alteration of gene expression by APAP, CCL, AD, and TC treatments
The affected genes in all treatment groups were classified into 6 functional categories according to "Gene Ontology." In all treatment groups, the number of affected genes related to oxidative stress or lipid metabolism or encoding transcription factors was higher than that for the other categories. Additionally, the number of affected genes at 24 hr tended to be greater than that at 6 hr in the above 3 categories for all treatment groups.
Observed gene networks in the APAP, CCL, AD, and TC treatment groups
From the result of pathway analysis using the Ingenuity system, networks regulated by specific tran- Results of hierarchical cluster analysis at 6 and 24 hr after dosing. Upper figure is for 6 hr; and the lower one, for 24 hr. In the figure, the animals are designated by group (control or treatment abbreviation) followed by their individual number. The abbreviations are as follow: Control, C and c; acetaminophen, :APAP and apap; carbon tetrachloride, CCL and ccl; amiodarone, AD and ad; and tetracycline, TC and tc. Circles indicate outliers, and these array data were omitted in the further analyses because they were considered not to reflect the toxicological signature.
scription factors were found for the lipid metabolismor oxidative stress-related genes in the case of all treatment groups. In the APAP treatment group, the lipid metabolism-related network regulated by sterol regulatory element binding protein 1 (SREBP1) or Myc was observed at 6 hr; and, furthermore, an oxidative stressrelated network regulated by nuclear factor (erythroidderived 2)-like 2 (Nrf2) was also found at 24 hr (Fig.  2) . In the CCL treatment group at both time points, lipid metabolism-and oxidative stress-related networks regulated by SREBP1 or Myc were noted (Fig.  3) . In the AD treatment group, a lipid metabolismrelated network regulated by SREBP1 or Myc was observed at 6 and 24 hr (Fig. 4) . On the other hand, in the TC treatment group, the number of detected networks was less than in the other treatment groups; however, a lipid metabolism-related network regulated by SREBP1 or Myc was detected (Fig. 5) . Totally, in all groups, the lipid metabolism-related gene network regulated by SREBP1 or Myc was down-regulated and, in some groups, oxidative stress-related gene networks mediated by Nrf2 or Myc were up-regulated.
Confirmation of the gene expression by real-time RT-PCR analysis
In the present study, to confirm the results of the microarray analysis, we performed real-time RT-PCR analysis. We investigated the following selected genes by pathway analysis in the corresponding groups and time points: 2 transcription factors, sterol regulatory element binding protein 1 (SREBP1) and nuclear factor (erythroid-derived 2)-like 2 (Nrf2); 2 lipid metabolism-related genes, fatty acid synthase (FASN) and sterol-CoA desaturase (SCD); and 3 oxidative stressrelated genes, heme oxygenase 1 (HMOX1), thioredoxine reductase 1 (TXNRD1), and GSR (glutathione reductase). The expression of lipid metabolism-related genes containing SREBP1 was decreased in almost all groups at both time points when compared with the control values (Table 4) . On the other hand, in APAP and CCL groups at 24 hr, a decrease in the expression of Nrf2 and increases in the expression of the oxidative stress-related genes were observed (Table 4) . These results correlated well with the results of the GeneChip microarray analysis.
DISCUSSION
In the present study, to confirm the quality and reliability of our microarray data, we performed the hierarchical cluster analysis of 31047 genes on the Genechip microarray chip. As a result, at both time points, the individual microarray data of each animal could be classified into 5 clusters. Each cluster correlated well with the treatment compounds, indicating that all array data reflected the changes induced by the drug treatment. Therefore, we considered this tool to be useful for the classification of toxicity and the array data to be reliable for further analysis. Furthermore, the fact that the clusters that correlated with the treatment compounds could be classified clearly even at 6 hr after treatment, at which time there were no remarkable findings upon histopathological examination or changes in serum chemistry parameters , suggests that hierarchical cluster analysis by using S-plus is a useful tool for prediction of early hepatotoxicity.
The results of the cluster analysis showed this approach to be useful to detect early hepatotoxicity and to classify that hepatotoxicity. However, we believe there is another approach in order to apply microarray data to predict heapatotoxity. That is investigation of toxicological biomarkers commonly changed by hepatotoxicants. In the present study, as shown Table 3 , many genes including oxidative stress-and lipid metabolism-related genes and transcription factors were affected among the 6 categories. Therefore, noting that the above genes included 3 categories, we performed network analysis by using Ingenuity Pathway Analysis software in order to examine the toxicological networks as possible biomarkers. Real-time RT-PCR analysis was also performed for confirming the expression of some genes.
In the acetaminophen (APAP) treatment group, there were several pathways regulated by a single transcription factor, i.e., nuclear factor (erythroid-derived 2)-like 2 (Nrf2) or Myc, at both time points. In these networks regulated by Nrf2, the gene expression of detoxification enzymes (GSTs) and antioxidants (GC LC, GCLM , GS R, TXNR D1 and H MOX1 ) increased at 24 hr. APAP, in overdose amount, depletes hepatic glutathione and leads to hepatocellular necrosis (Mitchell et al., 1973; Pumford et al., 1997) . In an in vitro model of rat hepatocytes in primary culture or in a proteomic analysis of hepatocytes, APAP-mediated oxidative stress was observed (Kikkawa et al., 2004; Yamamoto et al., 2005) . Furthermore, Nrf2 is known to regulate antioxidants, detoxification enzymes, and protective proteins (Rangasamy et al., 2004) ; and was reported to be one of the important transcription factors for oxidative stress or detoxification, based on the results of a study on Nrf2 knockout Table 5 .
Fig. 2.
Gene networks of CCL-treated liver at 6 and 24 hr revealed by using Ingenuity Pathway Analysis software.
Myc-, SREBF1 (SREBP1)-, and NFE2L2
(Nrf2)-related networks are indicated by the green outlines. Details are given in the legend of Fig. 2 .
Fig. 3.
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Gene networks of AD-treated liver at 6 and 24 hr revealed by use of Ingenuity Pathway Analysis software. Myc-and SREBF1 (SREBP1)-related networks are indicated by the green outlines. Details are given in the legend of Fig. 2 .
Fig. 4.
Gene networks of TC-treated liver at 6 and 24 hr revealed by using Ingenuity Pathway Analysis software. Myc-and SREBF1 (SREBP1)-related networks are outlined in green. Details are given in the legend of Fig. 2 .
Fig. 5.
Vol. 31 No. 5 mice treated with APAP (Chan et al., 2001) . Therefore, the above networks were considered to reflect the oxidative stress caused by APAP being basically consistent with the present results. Interestingly, in the APAP-treated liver at both 6 and 24 hrs, there was a decrease in the expression of the lipid metabolism network regulated by sterol regulatory element binding protein 1(SREBP1). In general, APAP doesn't enhance steatosis; nonetheless, this agent affected something related to lipid metabolism. However, the details of the mechanism are still uncertain. In the carbon tetrachloride (CCL) group, several networks regulated by SREBP1 or Myc were observed; and the expression of regulated genes such as those for sterol-CoA desaturase (SCD) and fatty acid synthases (FASNs) were decreased by CCL. SREBP1 is well known to regulate many lipid metabolism-related genes, such as those of SCD, FASNs, and apolioproteins (Shimano et al., 1999; Stoeckman and Towle, 2002) . CCL is known to induce hepatocellular necrosis Table 3 . Number of genes affected by hepatotoxicant treatment. Glycolysis/Glucogenesis Note. The genes affected by the 4 hepatotoxicants were categorized into 6 functional categories referred to as "Gene Ontology." Abbreviations of the treatment compounds are defined in the legend of Table 2. Oxidative stress-related genes GSR TXNRD1 HMOX1 Nrf2 Group 1.00 ± 0.27 1.00 ± 0.22 1.00 ± 0.12 1.00 ± 0.09 24 hr Control 3.32 ± 1.16* 6.87 ± 4.43* 4.57 ± 3.43 0.43 ± 0.08* 24 hr APAP 1.93 ± 0.42* 1.60 ± 0.24* 1.34 ± 0.25* 0.55 ± 0.16* 24 hr CCL Lipid metabolism-related genes SCD FASN SREBP1 Group 1.00 ± 0.23 1.00 ± 0.51 1.00 ± 0.41 6 hr Control 1.00 ± 0.45 1.00 ± 0.45 1.00 ± 0.24 24 hr 0.84 ± 0.30 0.37 ± 0.22 0.15 ± 0.09* 6 hr APAP 0.16 ± 0.11* 0.38 ± 0.23 0.53 ± 0.38 24 hr 0.56 ± 0.21* 1.26 ± 0.66 0.46 ± 0.28 6 hr CCL 0.67 ± 0.11 0.52 ± 0.14 0.58 ± 0.32 24 hr 0.53 ± 0.32* 0.66 ± 0.13 0.20 ± 0.03* 6 hr AD 0.29 ± 0.08* 0.35 ± 0.03 0.41 ± 0.24 24 hr 0.60 ± 0.14* 0.84 ± 0.45 0.37 ± 0.22* 6 hr TC 0.38 ± 0.39 1.10 ± 0.28 0.50 ± 0.20* 24 hr Note. Each value represents the mean ± standard deviation of 3-5 rats in each group. An asterisk indicates a statistically significant difference from the corresponding control. Abbreviations of the treatment compounds are given in the legend of Table 2 . Gene names and their abbreviations are as follow: nuclear factor (erythroid-derived 2)-like 2 (Nrf2), heme oxygenase 1 (HMOX1), thioredoxine reductase 1 (TXNRD1), glutathione reductase (GSR), sterol regulatory element binding protein 1 (SREBP1), fatty acid synthase (FASN) and sterol-CoA desaturase (SCD). and steatosis via the formation of CCl 3 radicals (Weber et al., 2003) , and the inhibition of lipoprotein secretion or fatty acid flow by CCl 3 radicals is considered to initiate the fatty change (Boll et al., 2001a (Boll et al., , 2001b . Therefore, this down-regulation of the lipid metabolic pathway may be attributable to feedback from lipid accumulation in the liver, as noted from the pathological examination. On the other hand, in the CCL-as well as APAP-treatment groups, up-regulation of oxidative stress-related genes such as HMOX1 or TXNRD1 regulated by Nrf2 was noted. HMOX1 was earlier reported to play an important protective role against oxidative injuries (Otterbein and Choi, 2000) , and CCL is known to induce HMOX1 gene expression (Nakahira et al., 2003) . In the present study, a similar induction was observed; and thus the Nrf2-mediated oxidative stress network is considered to reflect the reaction to oxidative stress.
In the amiodarone (AD) treatment group, SREBP1-and Myc-mediated lipid metabolism-related networks were affected. Of the genes regulated by the above transcription factors, there were SCD, FADS, and fatty acid elongation-related (ELOVL6) genes, as well as glycerolipid biosynthesis-related gene (GPAM), and lipogenesis and beta oxidation of lipidrelated genes (CPT1 and 2). AD has been reported to inhibit the hepatic mitochondrial N-oxidation of fatty acids, resulting in an increase in hepatic triglyceride accumulation and a decrease in the hepatic secretion of triglycerides into the blood (McCarthy et al., 2004) , as well as in microvesicular steatosis of the liver (Fromenty et al., 1990) . AD has been also reported to induce hypercholesterolemia associated with a decrease in liver LDL receptor mRNA (Hudig et al., 1994) . In the present study, an increase in serum cholesterol and a decrease in triglycerides were observed (data not shown). In light of the above findings, the altered expression of these genes by AD may reflect the increase in hepatic lipid levels induced by the inhibition of beta oxidation. In the tetracycline (TC) group, the lipid metabolism-related network regulated by SREBP1 or Myc was down-regulated. TC inhibits hepatic mitochondrial fatty acid beta-oxidation and thereby induces microvesicular steatosis (Fréneaux et al., 1988) . In the liver of the TC-treatment group at 24 hr, fatty deposits were observed. Therefore, the suppressed expression of genes in the lipid metabolism-related network may be considered a feedback effect of lipid accumulation in the TC-treated liver. Furthermore, in the TC treatment group, some oxidative stress-related genes were affected, as in the case of the other 3 compounds (Table  3) . However, in the pathway analysis, there was no clear effect of the drug on the oxidative-stress network; and therefore the mechanism underlying the effects of TC on oxidative stress-related genes might be different from that of the other compounds.
From the above findings by network analysis using Ingenuity Pathway Analysis software, 2 major networks, oxidative stress-and lipid metabolismrelated networks regulated by Nrf2, SREBP1 or Myc, were found to be affected in the 4 hepatotoxicant treatment groups. As changes in these networks reflected the toxicity, we suggest these networks to be good candidates for predicting the hepatotoxicity of drugs durig the development phase.
In summary, we administered 4 different hepatotoxicants, APAP, CCL, AD, and TC, to rats and investigated their effects on gene expression by using the Genechip microarray. The hierarchical cluster analysis showed that 5 treatment-related clusters could be classified at 6 hr when there were no noteworthy histopathological changes, indicating that this analysis is an available tool for early prediction of hepatotoxicity and classification of toxicity. Furthermore, we identified specific gene networks of oxidative stress and lipid metabolism regulated by transcription factors such as Nrf2 and SREBP1 in the hepatotoxicant-treated liver as candidate toxicological biomarkers. In light of the above, we suggest hierarchical cluster analysis for classification and early prediction of hepatotoxicity, as well as the pathway analysis for investigation of toxicological biomarkers to be useful tools for prediction of the hepatotoxicity of drugs under development.
